AI and Cancer Research ── Pancreatic ── 2026-11-19
Pancreatic cancer: treatment, trials and AI
- Abstract
Background: KRAS mutations occur in over 90% of pancreatic ductal adenocarcinomas (PDAC), and KRASG12D is the most frequent variant. G12D-selective inhibitors are now in clinical development, but computational pathology has so far predicted mutation status only at the gene level, leaving allele-specific prediction unexplored. Because genomic testing can be time-consuming and costly, a tool that predicts KRASG12D mutation status from routine hematoxylin and eosin (H&E) images could help identify patients for confirmatory molecular testing and potential treatment with KRASG12D inhibitors. Here we present a multi-scale framework that predicts KRASG12D status from H&E whole-slide images, with integration of computed tomography (CT).
Methods: Two public cohorts (TCGA, CPTAC) formed the training set, and an independent external cohort (Osaka Metropolitan University Hospital) served as validation. We developed a dual-magnification pipeline. In the high-magnification branch, a pathology foundation model (CONCH v1.5) was fine-tuned with low-rank adaptation (LoRA) and an attention-based multiple-instance learning head on 20× patches; in the low-magnification branch, a generative image model encoded a whole-slide overview. The two branches were integrated by late fusion into a multi-scale pathomics model, which was further combined with a radiomics model of CT.
Results: The multi-scale pathomics model reached a pooled internal test area under the receiver operating characteristic curve (AUC) of 0.611 and an external AUC of 0.701. In the external patients with CT, the combined model reached an AUC of 0.772, compared with 0.753 for pathomics alone.
Conclusions: KRASG12D status leaves a signal in routine H&E images and CT of PDAC that deep learning can detect and that transfers to an independent institution. After prospective validation, the framework might help prioritize patients for KRAS testing.
Journal IF-equivalent: 4.1 (OpenAlex 2-year mean citedness, value as of 2026-11-16, retrieved 2026-11-18; not the official Clarivate IF)Reference: Ma D, Sano T, Nishikubo H, Furukawa Y, Uchiyama K, Imanishi D, et al. Dual-Magnification Deep Learning Predicts KRASG12D Status from H&E Images of Pancreatic Cancer: A Multi-Cohort Study. Genes. 2026 Nov 15;17(11):1432. doi:10.3390/genes17111432.Checked: Abstract only